Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

CEO Francis deSouza Illumina's second major departure in weeks

Plus: Denner among those departing Biogen’s board, and updates from the White House, Delix, Heron and more

June 13, 2023 12:34 AM UTC

Three months after activist investor Carl Icahn launched his proxy battle with Illumina Inc. (NASDAQ:ILMN), the next-generation sequencing company announced the resignation of CEO Francis deSouza after 10 years in the role. deSouza’s is the second major departure in weeks, as Chairman John Thompson failed in his re-election bid in late May. Illumina named SVP and general counsel Charles Dadswell as interim CEO, with deSouza staying on in an advisory role until July 31 while the company seeks a permanent replacement.

Icahn, which held a 0.3% stake in Illumina at March 31, was seeking a change in Illumina’s board after publishing complaints about how the company had handled its $7.1 billion acquisition of Grail Inc., the completion of which is being blocked by the EU and the U.S. Federal Trade Commission (FTC). Illumina is down about 60% since its peak in August 2021. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article